Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a report released on Tuesday.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $53.00 price objective on the stock. Piper Jaffray Companies reissued a “hold” rating and issued a $45.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Janney Montgomery Scott started coverage on shares of Supernus Pharmaceuticals in a research note on Friday, July 14th. They issued a “neutral” rating and a $47.00 price objective on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $49.78.

Supernus Pharmaceuticals (SUPN) traded down $4.70 during mid-day trading on Tuesday, reaching $36.40. 2,741,006 shares of the company traded hands, compared to its average volume of 435,823. Supernus Pharmaceuticals has a 1 year low of $18.25 and a 1 year high of $50.04. The stock has a market cap of $1,890.00, a P/E ratio of 36.89, a price-to-earnings-growth ratio of 1.84 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.74 and a current ratio of 1.94.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The firm had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. research analysts anticipate that Supernus Pharmaceuticals will post 1.04 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Stock Rating Upgraded by Stifel Nicolaus” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-stock-rating-upgraded-by-stifel-nicolaus/1686480.html.

In related news, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the sale, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $623,250. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the completion of the sale, the vice president now directly owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Over the last three months, insiders sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. lifted its holdings in Supernus Pharmaceuticals by 77.4% in the 1st quarter. UBS Asset Management Americas Inc. now owns 17,737 shares of the specialty pharmaceutical company’s stock valued at $555,000 after purchasing an additional 7,737 shares in the last quarter. OppenheimerFunds Inc. purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $205,000. Teachers Advisors LLC lifted its holdings in Supernus Pharmaceuticals by 1.8% in the 1st quarter. Teachers Advisors LLC now owns 436,121 shares of the specialty pharmaceutical company’s stock valued at $13,651,000 after purchasing an additional 7,861 shares in the last quarter. Legal & General Group Plc lifted its holdings in Supernus Pharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 82,272 shares of the specialty pharmaceutical company’s stock valued at $2,575,000 after purchasing an additional 994 shares in the last quarter. Finally, Thrivent Financial For Lutherans lifted its holdings in Supernus Pharmaceuticals by 7.0% in the 1st quarter. Thrivent Financial For Lutherans now owns 28,130 shares of the specialty pharmaceutical company’s stock valued at $880,000 after purchasing an additional 1,850 shares in the last quarter. 96.11% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.